|
|
|
The IBCG (International Bladder Cancer Group) returned to the AUA. This forum brings together multidisciplinary experts addressing common dilemmas and challenges in the management of bladder cancer. UroToday is the IBCG education partner.
|
|
|
|
|
|
IBCG Bladder Cancer Forum |
|
|
|
|
|
| Treatment Options for Advanced Urothelial Cancer Post-EV-302 |
Shilpa Gupta, MD, & Karima Oualla, MD, MSc
Pat Hensley discusses first-line systemic therapy selection for advanced urothelial carcinoma with Karima Oualla and Shilpa Gupta. They highlight cisplatin-based chemotherapy as the traditional mainstay but shift focus to the EV-302 trial, which explores enfortumab vedotin (EV) and pembrolizumab (pembro) as a new first-line combination.
|
|
|
|
|
|
|
|
|
|
|
| Exploring the Complexities of Bladder Cancer Surveillance: Cytology, UroVysion, and Beyond |
Kelly Bree, MD & Kamal Pohar, MD
Ashish Kamat engages with Kamal Pohar and Kelly Bree on bladder cancer surveillance. They discuss the ongoing debate about the utility of various urinary markers in monitoring bladder cancer. |
|
|
|
|
|
|
|
|
|
|
|
Managing Variant Histology in High-Risk Non-Muscle Invasive Bladder Cancer
|
Paolo Gontero, MD & Michael Cookson, MD, MMHC
Ashish Kamat hosts Paolo Gontero and Michael Cookson to discuss managing high-risk bladder cancer with variant histology. They address the challenges of treating these cases, given the variability in pathology reports and treatment strategies. |
|
|
|
|
|
|
|
|
|
|
|
To TURBT or Not to TURBT? Evaluating Treatment Options for Recurrent Low-Grade, Intermediate-Risk Bladder Tumors
|
Sarah Psutka, MD & Param Mariappan, MBBS, Ph.D., FRCS(Urol), FEBU, FRCSEd
Ashish Kamat is joined by Paramananthan (Param) Mariappan and Sarah Psutka. They discuss managing patients with low-grade intermediate-risk bladder cancer, focusing on treatment, surveillance, and de-escalation strategies. |
|
|
|
|
|
|
|
|
|
|
|
The Evolving Role of Radical Cystectomy in the Era of Bladder-Sparing Therapies
|
Sima Porten, MD, MPH & Roger Li, MD
Ashish Kamat hosts Sima Porten and Roger Li to discuss the management of BCG-unresponsive bladder cancer. They emphasize personalized patient care, starting by understanding patients' goals and risk tolerance. |
|
|
|
|
|
|
|
|
|
|
|
Timing and Rationale for Repeat TURBT: Perspectives on Improving Bladder Cancer Outcomes
|
Badrinath Konety, MD, FACS, MBA, & Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery)
Ashish Kamat discusses the controversial topic of repeat transurethral resection (reTUR) for high-grade non-muscle-invasive bladder cancer with Badrinath (Badri) Konety and Jeremy Teoh.
|
|
|
|
|
|
|
|
|
|
|
|
Defining Standard and Extended Pelvic Lymphadenectomy in Bladder Cancer Surgery
|
Seth Lerner, MD, FACS, & Siamak Daneshmand, MD
Pat Hensley hosts a discussion on the role of pelvic lymphadenectomy during radical cystectomy for muscle-invasive bladder cancer. Joining him are Seth Lerner and Sia Daneshmand, who contribute their insights on the evolution of surgical guidelines and the integration of new biomarkers in the treatment of advanced bladder cancer.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
